EUROPA PASA DE TENER DOS TRATAMIENTOS SCLC-ES EN PRIMERA LINEA INMUNOTERAPIA ( ATEZOLIZUMAB
Y DURVALUMAB ) ... A TENER CUATRO ( ATEZOLIZUMAB, DURVALUMAB , SERPLULIMAB Y TISLELIZUMAB ) .
08 agosto 2020
JazzPharma . UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP .
